AstraZeneca and MedImmune in oncology research deals
January 12, 2016Manufacturing and Production, Research and Development AstraZeneca, Incyte, MedImmune, Moderna Therapeutics
AstraZeneca and its biologics arm MedImmune are launching new agreements with partner companies, to develop new targets for cancer, and …
Pfizer raised 100 US drug prices 1 January
January 12, 2016Manufacturing and Production, Sales and Marketing Allergan, Drug pricing, Lyrica, Pfizer, ibrance, tax inversion
Drugs giant Pfizer raised the prices of more than 100 of its drugs in the US on 1 January, in …
Mark Alles is new chief executive of Celgene
January 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing Celgene, Mark Alles
Celgene president and chief operating officer Mike Alles has been promoted to the top job after an executive restructure at …
The Pharmafocus debate: Can ultra-orphan drugs be made cheaper?
January 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing Drug pricing, Duchenne Muscular Dystrophy, Translarne, access to medicines, ataluren, muscular dystrophy, rare disease, ultra orphan drugs, ultra-orphan drugs
The recent reimbursement wrangle between PTC Therapeutics and NICE, the UK healthcare watchdog, has once again raised difficult questions about …
Roche snaps up Tensha Therapeutics for up to $535m
January 12, 2016Manufacturing and Production, Research and Development Roche, Tensha Therapeutics
Roche has acquired Tensha Therapeutics, a privately-held company based in Cambridge, Massachusetts for up to $535 million.The deal that gives …
Genomics appoints Sekar Kathiresan as scientific advisory board chair
January 11, 2016Sales and Marketing genomics
Genomics has appointed Dr Sekar Kathiresan as chair of the company’s newly-formed scientific advisory board as chair, with immediate effect. Dr …
AbbVie tests new hepatitis C drug in Phase III trials
January 11, 2016Research and Development AbbVie, clinical trials, hepatitis C, phase III
AbbVie has announced it has begun six global Phase III trials of its once-daily, ribavirin-free investigational hepatitis C virus regimen, …
Three appointments in AstraZeneca’s global media relations team
January 11, 2016Medical Communications AstraZeneca
Neil Burrows has joined as head of global media relations, following Esra Erkal-Paler’s promotion to head of global external communications.Burrows …
Shire and Baxalta reach $32 billion merger agreement
January 11, 2016Manufacturing and Production, Sales and Marketing Baxalta, Shire, mergers, mergers and acquisitions
One of the industry’s longest-running M&A sagas has finally reached a conclusion, with Shire and Baxalta announcing a $32 billion …
AbbVie begins late stage trials of rheumatoid arthritis drug
January 11, 2016Manufacturing and Production, Research and Development, Sales and Marketing ABT-494, AbbVie, F-star, JAK-1 inhibitor, rheumatoid arthritis
AbbVie has begun a large phase III clinical trial programme for its next-generation rheumatoid arthritis (RA) treatment ABT-494, which the …
Sanofi seals double oncology research deals
January 11, 2016Research and Development, Sales and Marketing Sanofi, Warp Drive Bio, antibodies, collaboration, immuno-oncology, research
Sanofi has signed two separate research agreements for €1.2 billion, which will give the French firm licensing rights to potential …
Novartis expands immuno-oncology programme
January 11, 2016Research and Development, Sales and Marketing Cancer, Novartis, Surface Oncology, collaboration, immuno-oncology
Novartis has further bolstered its immuno-oncology pipeline through a strategic alliance and licensing agreement with Surface Oncology, as it moves …
GSK explains decision to halt payments to doctors
January 8, 2016Medical Communications, Sales and Marketing GSK, doctor payments, medical education, transparency
GSK has put into practice its pledge to halt payments to doctors to promote its products at medical seminars – …
Mylan announces Momenta collaboration to develop six biosimilars
January 8, 2016Manufacturing and Production, Sales and Marketing Heather Bresch, Momenta, Mylan, biosimilars
Mylan has entered an exclusive global collaboration agreement with Momenta Pharmaceuticals, to develop, manufacture and commercialise six of Momenta’s biosimilar …
Teva launches biosimilar fertility treatment in the UK
January 8, 2016Manufacturing and Production, Sales and Marketing Ovaleap, Teva, biosimilar
Teva has launched its biosimilar version of Merck’s fertility treatment Gonal-f in the UK, potentially bringing a more affordable version …
PCI Pharma Services expands customer support portal
January 8, 2016Business Services PCI Pharma Services
PCI Pharma Services has announced the expansion of its proprietary client services online portal, Webflow, into all PCI Clinical Services …
Investment group renews calls for GSK to split
January 8, 2016Medical Communications, Sales and Marketing GSK, Neil Woodford, investment, restructure
Multi-million pound fund manager Neil Woodford has renewed his call for GSK to break up into separate business units, amid …
Why 2016 could be a make or break year for Valeant
January 8, 2016Medical Communications, Sales and Marketing Howard Schiller, J. Michael Pearson, Michael Pearson, Valeant
This could prove a make-or-break year for Valeant.The specialist drug company begins 2016 with a reputation damaged by allegations of …
FDA review for Sanofi and Regeneron’s biologic arthritis drug
January 8, 2016Medical Communications, Sales and Marketing FDA, Regeneron, Sanofi, biologics, rheumatoid arthritis, sarilumab
The FDA has accepted for review a Biologics License Application (BLA) from Sanofi and Regeneron for the rheumatoid arthritis treatment …
Roche presents new data for advanced bladder cancer immunotherapy
January 8, 2016Medical Communications, Research and Development Roche, atezolizumab, bladder cancer
Roche has announced updated results from a pivotal Phase II study, showing its investigational cancer immunotherapy atezolizumab extended median progression …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
